Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Adial Pharmaceuticals, Inc. (ADIL)

5.05 +1.34 (+36.12%)
At close: October 28 at 4:00:00 PM EDT
4.86 -0.19 (-3.76%)
After hours: October 28 at 7:52:34 PM EDT
Ticker Change
ADIL is trading under new symbol AZR effective Oct. 29, 2026
Chart Range Bar
Loading chart for ADIL
Chart does not reflect overnight price.
  • Previous Close 3.71
  • Open 3.83
  • Bid 4.25 x 200
  • Ask 4.11 x 1800
  • Day's Range 3.82 - 5.15
  • 52 Week Range 1.31 - 9.25
  • Volume 83,085
  • Avg. Volume 56,620
  • Market Cap (intraday) 13.261M
  • Beta (5Y Monthly) 1.50
  • PE Ratio (TTM) --
  • EPS (TTM) -20.65
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 8.33

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.

www.adial.com

5

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ADIL
8.18%
S&P 500 (^GSPC)
13.13%

1-Year Return

ADIL
46.84%
S&P 500 (^GSPC)
12.38%

3-Year Return

ADIL
90.05%
S&P 500 (^GSPC)
88.08%

5-Year Return

ADIL
99.76%
S&P 500 (^GSPC)
68.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings -51.99M
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-50M
-40M
-30M
-20M
-10M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

6.00
8.33 Average
5.05 Current
11.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/3/2026
Analyst Alliance Global Partners
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 11

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -40.02%

  • Return on Equity (ttm)

    -2,011.64%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -57.8M

  • Diluted EPS (ttm)

    -20.65

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    28.71M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.93M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: